RNS Number : 4549V

OptiBiotix Health PLC

04 December 2023

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Directorate change

OptiBiotix Health p lc (AI M: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, a nnounces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023 .

Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's GBP800m UK pension scheme.

Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support the focus on driving each business unit and the Group to profitability.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Graham Lloyd Myers (aged 60):

  Current Directorships     Previous Directorships held in the 
                             past five years 
  Croda Pension Trustees 
   Limited                  Bio Futures PI Limited 
  Croda Trustees Limited    Cargill Bioindustrial BV (Previously 
                             Croda Nederland BV) 
                            Cowick Insurance Services Limited 
                            Croda (Thailand) Co Ltd 
                            Croda Cosmetics & Toiletries Limited 
                            Croda Food Services Limited 
                            Croda India Company Private Limited 
                            Croda Investments Limited 
                            Croda Investments No 2 Limited 
                            Croda Investments No 3 Limited 
                            Croda Overseas Holdings Limited 
                            Croda Polymers International Limited 
                            Croda World Traders Limited 
                            Enza Biotech AB 
                            Lanxess Urethanes UK Ltd 
                            P. I. Bioscience Limited 
                            Plant Impact Limited 
                            PT. Croda Indonesia LLC 
                            Uniqema Limited 
                            Uniqema UK Limited 

Graham Myers holds no ordinary shares, options or warrants over ordinary shares in the Company.

There is no further information regarding Graham Myers required to be disclosed under the AIM Rules.

Stephen OHara, CEO of OptiBiotix commented: " We are pleased to confirm the appointment of Graham Myers as Finance Director. The appointment reflects the progress we have made in 2023 after a difficult 2022 and the Board's focus on controlling costs and building revenues to create a profitable international business with well-known global brands".

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

  OptiBiotix Health plc                              www.optibiotix.com 
  Neil Davidson, Chairman                          Contact via Walbrook 
  Stephen O'Hara, Chief Executive 
  Cairn Financial Advisers LLP (NOMAD)               Tel: 020 7213 0880 
  Liam Murray / Jo Turner / Ludovico Lazzaretti 
  Peterhouse Capital Limited (Joint Broker)          Tel: 020 7220 9797 
  Duncan Vasey/ Lucy Williams 
  Walbrook PR Ltd                                    Mob: 07876 741 001 
  Anna Dunphy 
   About OptiBiotix   -   www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identi ed by their use of terms and phrases such as "believe", "could", "should" "envisage", "estimate", "intend", "may", "plan", "potentially", "expect", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements re ect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

December 04, 2023 02:00 ET (07:00 GMT)

Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Gen 2024 a Feb 2024 Clicca qui per i Grafici di Optibiotix Health
Grafico Azioni Optibiotix Health (LSE:OPTI)
Da Feb 2023 a Feb 2024 Clicca qui per i Grafici di Optibiotix Health